D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
1310PSurvival and safety of atezolizumab by best overall response (BOR) in the phase III NSCLC OAK study
F. De Marinis,Fabrice Barlesi,Achim Rittmeyer,J. von Pawel,J-Y. Han,Mark Kozloff,Alexander I. Spira,Louis Fehrenbacher,David R. Gandara,Wei Yu,Pei He,Cindy Yun,Marcus Ballinger,M. Gandhi,S. Gadgeel +14 more
Journal ArticleDOI
Dual Inhibition: Combining Epidermal Growth Factor–Targeted Therapies in Non–Small-Cell Lung Cancer
TL;DR: The use of both strategies simultaneously to block the EGFR signaling cascade, so-called dual inhibition, might theoretically overcome limitations and improve efficacy in treatment of advanced non-small-cell lung cancer.
Journal ArticleDOI
Patient selection for cetuximab in NSCLC: A systematic review of candidate predictive biomarkers.
Christopher T. Harbison,Christopher Stroh,Thomas J. Lynch,David R. Gandara,Kenneth J. O'Byrne,R. Pirker,S. Maier,Ilhan Celik,Martin R. Weber,Shirin Khambata-Ford +9 more
TL;DR: Cetuximab improved overall survival (OS) in first-line advanced NSCLC in a pivotal trial including all histologies (FLEX) as mentioned in this paper, and other phase II/III trials have tested cetux-imab with seve...
Journal ArticleDOI
OA06.01 Case-Series Study in Ever- and Never-Smoking Females and Males with NSCLC: Exposures, Tumor Factors, Biology and Survival (SWOG S0424)
Kathy S. Albain,Amy K. Darke,P. C. Mack,Mary W. Redman,Ting-Yuan Cheng,James Moon,W. S. Holland,Alain C. Borczuk,C. Chay,P. Morris,Eric Vallières,Robert A. Kratzke,Julian R. Molina,Jill M. Kolesar,Yuhchyau Chen,Robert MacRae,Seiji Matsumoto,Mary E. Reid,Gary Zirpoli,Warren Davis,Rochelle Payne Ondracek,Wiam Bshara,Angela Omilian,David R. Gandara,Karen Kelly,Regina M. Santella,Christine B. Ambrosone +26 more
Journal ArticleDOI
Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN).
Joshua A. Roth,Meghna S. Trivedi,Stacy W. Gray,Donald L. Patrick,Deborah M Delaney,Kate Watabayashi,Paul Litwin,Parth D. Shah,Katherine D. Crew,Monica Yee,Mary W. Redman,Joseph M. Unger,Vassiliki A. Papadimitrakopoulou,Vassiliki A. Papadimitrakopoulou,Judy Johnson,Karen Kelly,David R. Gandara,Roy S. Herbst,Dawn L. Hershman,Scott D. Ramsey,Scott D. Ramsey +20 more
TL;DR: In this article, the authors proposed a new paradigm in oncology clinical trials using biomarker-driven master protocols, but their complex designs and wide-ranging genomic results returned can be difficult to communicate.